TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05703464
Drug: Elobixibat 10mg
Normalized name: elobixibat
DrugBank: Elobixibat (DB12486)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Patients of chronic constipation with loss of defecation desire are administered Elobixibat 10mg for 4 weeks
Study: NCT04672876
Drug: Telotristat Ethyl Oral Tablet
Normalized name: telotristat ethyl Oral Tablet
DrugBank: Telotristat ethyl (DB12095)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: XERMELO is a prescription pill, used along with somatostatin analog (SSA) therapy, for Carcinoid Syndrome diarrhea in adults who are not adequately controlled by SSA therapy. The drug is currently FDA-approved for this use but this study has received special approval from the FDA (under an Investigational Drug Application) to study telotristat ethyl in individuals with carcinoid tumors who plan to undergo surgery.
Study: NCT05546320
Drug: Aspirin 100mg
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anticoagulation or anti-platelet or migraine medication therapy will be provided for different groups.
Study: NCT05546320
Drug: Metoprolol 25 Mg Oral Tablet
Normalized name: metoprolol 25 mg oral tablet
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoprolol 25mg will be provided for the participants twice a day.
Study: NCT05546320
Drug: Clopidogrel 75mg
Normalized name: clopidogrel 75 MG
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clopidogrel 75mg will be provided for the participant once a day.
Study: NCT05546320
Drug: Rivaroxaban 20mg
Normalized name: RIVAROXABAN 20MG TAB
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban 20mg will be provided for the participant once a day.
Study: NCT06169956
Drug: Neoadjuvant nivolumab in combination with platinum-based chemotherapy
Normalized name: platinum
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Neoadjuvant treatment of resectable non-small cell lung cancer with nivolumab in combination with chemotherapy according to current summary of product characteristics
Study: NCT06118333
Drug: BL-B01D1
Normalized name: BL-1020
DrugBank: BL-1020 (DB05687)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration by intravenous infusion
Study: NCT06118333
Drug: gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administration by intravenous infusion
Study: NCT06118333
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration by intravenous infusion
Study: NCT05453903
Drug: Bleximenib
Normalized name: Bleximenib
DrugBank: Bleximenib (DB19328)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive bleximenib.
Study: NCT05453903
Drug: Azacitidine (AZA)
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive AZA.
Study: NCT05453903
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive cytarabine.
Study: NCT05453903
Drug: Daunorubicin or Idarubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive daunorubicin or idarubicin.
Study: NCT04535557
Drug: Mobocertinib 160 mg
Normalized name: Mobocertinib
DrugBank: Mobocertinib (DB16390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mobocertinib 160 mg, capsule, orally, once daily in 28-day treatment cycles for up to approximately 4 months.
Study: NCT06196697
Drug: SOX
Normalized name: Vasoxyl
DrugBank: Methoxamine (DB00723)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive AK104 and AK112 in combination withSOX(oxaliplatin and Tegafur)
Study: NCT00683306
Drug: ZD1839 (Iressa)
Normalized name: Iressa
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gefitinib supplied for oral use at the dose and schedule that the patient received in the previous gefitinib clinical study. In the case of placebo patients, the gefitinib dose will be as described in the protocol of their previous gefitinib clinical study.
Study: NCT04754399
Drug: Cannabidiol (CBD)
Normalized name: cannabidiol (CBD)
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: week 1: 25 mg twice daily, approximately 12 hours apart, with food~week 2: 50 mg twice daily, approximately 12 hours apart, with food~week 3: 75 mg twice daily, approximately 12 hours apart, with food~week 4+: 100 mg twice daily, approximately 12 hours apart, with food
Study: NCT05527899
Drug: Zinc gluconate
Normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 and 60 mg/d of zinc gluconate
Study: NCT04839393
Drug: PF-06882961 + PF-06865571
Normalized name: PF-06882961
DrugBank: PF-06882961 (DB16043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Period 1: PF-06865571 300 mg single dose (Day 1), Period 2: PF-06882961 10 mg twice daily dose titration up to 200 mg twice daily dosing (Days 3-46), Period 3: PF-06865571 300 mg single dose (Day 47) and PF-06882961 200 mg twice daily dosing (Days 47-48), Period 4: PF-06865571 300 mg twice daily dosing and PF-06882961 200 mg twice daily dosing (Days 49-62)
Study: NCT05411380
Drug: Tucidinostat
Normalized name: tucidinostat
DrugBank: Tucidinostat (DB06334)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: 20mg each time, orally 30 minutes after dinner, 3 weeks for a cycle, administered on day 1, day 4, day 8, day 11, day 15,and day 18 of each cycle (twice a week, at least 3 days between each administration)
Study: NCT06093971
Drug: remimazolam
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Remimazolam is administered for anesthesia induction.
Study: NCT06093971
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol is administered for anesthesia induction.
Study: NCT06199271
Drug: Adebrelimab and dalpiciclib
Normalized name: cytarabine and daunorubicin
DrugBank: Adebrelimab (DB16412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Before surgery, the eligible patients received 3 cycles of adebrelimab (1200 mg intravenously every 3 weeks, Day 1, 22 and 43) and 2 cycles of dalpiciclib (150 mg, po, every 4 weeks, day 1-21 and 29-49). Administration dose adjustments were permitted according to the haematological or non-haematological toxicity.
Study: NCT05095311
Drug: Cetirizine HCl
Normalized name: cetirizine HCl
DrugBank: Cetirizine (DB00341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eight participants will be administered 10 mg of cetirizine HCl to examine whether this drug can improve their oxyhemoglobin saturation during exercise.
Study: NCT04987463
Drug: Vigabatrin
Normalized name: Vigabatrin
DrugBank: Vigabatrin (DB01080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vigabatrin in capsules administered orally, initially (between V1 and V2) once daily in the evening,and starting from V2 administered two times daily.
Study: NCT04987463
Drug: Rapamycin
Normalized name: Rapamycin
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rapamycin in liquid administered orally, in the morning, every other day or daily depending on the patient's body weight. The starting dose of rapamycin will be calculated according to the body weight of the patient measured at V1.
Study: NCT04850378
Drug: Dalteparin
Normalized name: dalteparin
DrugBank: Dalteparin (DB06779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Dalteparin 200 units/kg once a day for 4-7 days.
Study: NCT04850378
Drug: Apixaban
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Drug: Apixaban 5 mg twice a day for 4-7 days.
Study: NCT06512883
Drug: Benralizumab
Normalized name: Benralizumab
DrugBank: Benralizumab (DB12023)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Benralizumab will be administered as SC injection on Q4W.
Study: NCT05398705
Drug: Cepharanthine
Normalized name: Cepharanthine
DrugBank: Cepharanthine (DB16824)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Low-dose: Day 1\~5: 20mg, Q8H X 5 days (60mg/day)+SMT
Study: NCT05398705
Drug: Cepharanthine
Normalized name: Cepharanthine
DrugBank: Cepharanthine (DB16824)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: High-dose: Day 1\~5: 40mg, Q8H X 5 days (120mg/day) +SMT~SMT:standardized medical treatment according to Scheme for Diagnosis and Treatment of 2019 Novel Coronavirus Pneumonia (The 9th Trial Edition) from health commission of China, including bed rest, adequate energy and nutrition, pay attention to water and electrolyte balance to maintain a stable internal environment, closely monitor and Chinese traditional medicine, etc.
Study: NCT06395519
Drug: ETX-19477
Normalized name: Polygonatum biflorum root etxract
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral medication taken daily
Study: NCT04842552
Drug: Hydralazine hydrochloride 25mg tablets
Normalized name: hydralazine
DrugBank: Hydralazine (DB01275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydralazine hydrochloride 25mg tablets three time daily for 365 days (one year)
Study: NCT05569993
Drug: Glutamine
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: .3 mg/kg of glutamine
Study: NCT05908747
Drug: surufatinib + gemcitabine + nab-paclitaxel
Normalized name: Paclitaxel
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: surufatinib: 250mg, QD po; nab-paclitaxel: 125mg/m2, I.V., D1/8/15, Q4W; gemcitabine: 1000/m2, ivgtt for more than 30min, D1/8/15, Q4W
Study: NCT04884971
Drug: Intestinal microbiota transplant (IMT)
Normalized name: Washed Microbiota Transplantation
DrugBank: Washed Microbiota Transplantation (DB15745)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two size 00 capsules from a single lot will be taken daily. Approximately 2.0 x 10\^11 bacteria from a healthy donor are contained in each capsule.
Study: NCT00106834
Drug: Infliximab
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT05250011
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dapagliflozin, prescribed as per approved indication and current medical practice. Participants will not receive any experimental disease management intervention or experimental treatment as a consequence of their participation in the study.
Study: NCT05459558
Drug: Experimental Dentifrice 1
Normalized name: stannous fluoride
DrugBank: Rice (DB10563)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 percent (%) potassium nitrate (KNO3) dentifrice with 1% alumina and 5% sodium tripolyphosphate (STP).
Study: NCT05459558
Drug: Experimental Dentifrice 2
Normalized name: sodium fluoride
DrugBank: Rice (DB10563)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5% KNO3 dentifrice with 1% alumina, 5% STP and 2% high cleaning silica.
Study: NCT05459558
Drug: Reference Dentifrice
Normalized name: stannous fluoride
DrugBank: Rice (DB10563)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Regular Fluoride Dentifrice.
Study: NCT04831996
Drug: parsaclisib
Normalized name: Parsaclisib
DrugBank: Parsaclisib (DB14867)
Approvals — FDA: no, EMA: no, PMDA: no
Description: parsaclisib will be administered orally after 8 hours of fasting.
Study: NCT04844983
Drug: STP705
Normalized name: STP705 (small interfering RNA (siRNA) therapeutic directed against transforming growth factor-beta 1 (TGF-beta 1) and cyclo-oxygenase-2 (COX-2))
DrugBank: Cotsiranib (DB18404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The STP705 drug substance is composed of two siRNA oligonucleotides, targeting TGF-β1 and COX-2 mRNA respectively.
Study: NCT05768997
Drug: Ferric Derisomaltose Injection
Normalized name: ferric derisomaltose Injection
DrugBank: Ferric derisomaltose (DB15617)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferric derisomaltose/iron isomaltoside (as iron) (0 weeks): 20mg/kg, diluted in 250ml of 0.9% physiological saline and injected intravenously over 30-60 minutes
Study: NCT05768997
Drug: Darbepoetin Alfa Injection
Normalized name: darbepoetin alfa Injection
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoietin alfa (0 weeks, 3 weeks, 6 weeks, 9 weeks): 6.75㎍/kg, subcutaneous or intravenous administration
Study: NCT05750628
Drug: KAE609 (Cipargamin)
Normalized name: Cipargamin
DrugBank: Cipargamin (DB12306)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral KAE609 (Cipargamin)
Study: NCT05750628
Drug: SoC (Coartem)
Normalized name: Coartem
DrugBank: Artemether (DB06697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SoC (Coartem)
Study: NCT00000888
Drug: Ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00000888
Drug: Lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00000888
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04542434
Drug: Niclosamide Oral Tablet
Normalized name: niclosamide Oral Tablet
DrugBank: Niclosamide (DB06803)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Niclosamide tablets 400 mg 3 times daily for 14 days
Study: NCT05048615
Drug: Venetoclax 100 MG
Normalized name: venetoclax 100 MG
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive oral Venetoclax at a fixed dose of 100mg/day from day 1 to day 21 per cycle for a maximum of 2 cycles.
Study: NCT05048615
Drug: Itraconazole capsule
Normalized name: Itraconazole Capsules
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive oral itraconazole at a dose of 100 mg every 12 hours from day 1 to day 21.
Study: NCT05048615
Drug: Azacitidine Injection
Normalized name: azacitidine Injection
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive a maximum of two cycles of daily subcutaneous Azacitidine at a dose of 75 mg/m2 (maximum 100 mg) from day 1 to day 7.
Study: NCT04740996
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab (formerly lambrolizumab, brand name Keytruda) is a humanized antibody used in cancer immunotherapy. This includes to treat melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, and stomach cancer.
Study: NCT05387512
Drug: Camrelizumab
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with EGFR-mutation-negative and ALK-negative advanced non-squamous non-small cell lung cancer were treated with first-line chemotherapy in combination with camrelizumab.
Study: NCT05180890
Drug: Danavorexton
Normalized name: Danavorexton
DrugBank: Danavorexton (DB16962)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danavorexton intravenous infusion.
Study: NCT04876131
Drug: Benzylpenicillin - single dose
Normalized name: benzylpenicillin
DrugBank: Benzylpenicillin (DB01053)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive a single dose of IV antibiotic (benzylpenicillin).~Benzylpenicillin dosing: 1 month - 18 years, IV or Intramuscular (IM) 30 mg/kg (maximum 1.2 g) every 6 hours.
Study: NCT04876131
Drug: Benzylpenicillin - three days
Normalized name: three-lobe sage extract
DrugBank: Benzylpenicillin (DB01053)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive three days of this IV antibiotic (benzylpenicillin).~Benzylpenicillin dosing: 1 month - 18 years, IV or Intramuscular (IM) 30 mg/kg (maximum 1.2 g) every 6 hours. For severe infections, use up to 60 mg/kg (maximum 2.4 g) every 4-6 hours.
Study: NCT04992624
Drug: Cannabidiol (CBD)
Normalized name: cannabidiol (CBD)
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Epidiolex doses will be 0.37 milliliter (mL) for seven days of treatment and then 0.75 mL two times a day (b.i.d) for the remaining days of this treatment.~In the event that 2.5 mg capsules of dronabinal capsules become unavailable, an equivalent product will be issued to participants and the comparator and placebo arms will be correspondingly adjusted to preserve blinding. If a participant's dose is not well-tolerated, the participant may initiate dose reductions with the study team.~Participants will be instructed to eat a meal or snack greater than one hour after taking study drug.
Study: NCT04992624
Drug: Tetrahydrocannabinol (Marinol® or generic equivalent (e.g., dronabinol)
Normalized name: dronabinol Oral Capsule [Marinol]
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dronabinol Capsules doses will be 2.5 mg b.i.d. for seven days of treatment and then 5 mg b.i.d. for the remaining days of this treatment.~In the event that 2.5 mg capsules of dronabinal capsules become unavailable, an equivalent product will be issued to participants and the comparator and placebo arms will be correspondingly adjusted to preserve blinding. If a participant's dose is not well-tolerated, the participant may initiate dose reductions with the study team.~Participants will be instructed to eat a meal or snack greater than one hour after taking study drug.
Study: NCT04671355
Drug: Beclometasone Dipropionate / Formoterol Fumarate / Glycopyrronium 100/6/10 mcg
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pressurized metered dose inhaler
Study: NCT04671355
Drug: Fluticasone Furoate / Vilanterol Trifenatate 100/25 mcg
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dry powder inhaler
Study: NCT04801043
Drug: Imipenem/Cilastatin
Normalized name: imipenem/cilastatin/relebactam
DrugBank: Cilastatin (DB01597)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500mg/500mg IV over 60 minutes as a single dose
Study: NCT05998837
Drug: Dapagliflozin 10mg Tab
Normalized name: DAPAGLIFLOZIN 10MG TAB
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dapagliflozin will be add on RAAS-i titrated with the aim to reach optimal blood pressure control as defined by European Society of Hypertension (i.e., 120-130/70-80 mmHg) in all subject.~Prior to randomization all the patient with Type 2 Diabetes must have undergone at least 4 weeks of therapy with metformin and/or repaglinide
Study: NCT05805605
Drug: Allopurinol 300 MG
Normalized name: allopurinol 300 MG
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300 mg/day from day -7 to day 0. Allopurinol 150mg/m2/day for pediatric participants.
Study: NCT05805605
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/m2 IV over 1 hour. Administered on day -6 to day -2.
Study: NCT05805605
Drug: Sirolimus Pill
Normalized name: sirolimus Pill
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: All participants begin +5 to day +100.~Loading dose on day +5 of 5 mg/m2/day orally once (max dose of 8 mg).~Maintenance dose 2.5 mg/m2 orally daily to maintain a level of 8-12 ng/ml (max dose of 4 mg).
Study: NCT05805605
Drug: Mycophenolate Mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All patients begin day +5 through day +35.~3 gram/day IV/PO for patients who are ≥ 40 kg divided in 2 doses. In obese patients (\>125% IBW) 15 mg/kg every 12 hours may be considered. Pediatric patients will receive MMF at the dose of 15 mg/kg/dose (maximum of 1 gram per dose) every 8 hours.
Study: NCT06255665
Drug: JNJ-79032421
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-79032421 will be administered.
Study: NCT06255665
Drug: JNJ-79032421
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-79032421 will be administered at RP2D regimen.
Study: NCT06197308
Drug: oral vancomycin and oral amoxicillin
Normalized name: vancomycin Oral Capsule
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In this study, PSC patients will receive an antibiotic preconditioning regimen of oral vancomycin (500 mg liquid twice a day) for 28 days and oral amoxicillin (1000 mg twice a day) for 7 days (during the last 7 days of the oral vancomycin). Following vancomycin and amoxicillin, encapsulated, freeze-dried microbiota preparation (MTP-101C) will be administered - dosed at ≥ 5 x 10\^11 bacteria (five capsules) daily for 3 days followed by ≥ 2 x 10\^11 bacteria (two capsules) for 11 days - for a total of 14 days of MTP-101C; total of 37 capsules.
Study: NCT05652335
Drug: JNJ-79635322
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-79635322 will be administered as SC injection.
Study: NCT05564052
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ibrutinib capsules will be administered orally.
Study: NCT05564052
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide capsules will be administered orally.
Study: NCT05564052
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab will be administered IV.
Study: NCT05564052
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib will be administered either intravenously or subcutaneously.
Study: NCT04987931
Drug: Talazoparib
Normalized name: TALAZOPARIB
DrugBank: Talazoparib (DB11760)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This retrospective chart review study focuses on patients with HER2- ABC with gBRCA1/2m initiating talazoparib on or after October 16, 2018 and ≥18 years of age at initiation of talazoparib.
Study: NCT05176925
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tislelizumab 200mg IV D1, Q3W
Study: NCT05176925
Drug: Sitravatinib
Normalized name: Sitravatinib
DrugBank: Sitravatinib (DB15036)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The starting dose of sitravatinib in this study is 70 mg, oral once daily. After receiving 2 cycles of starting dose at 70 mg once daily with sitravatinib, if patients were tolerated well with study treatment (without AEs definitely related to sitravatinib nor TRAEs leading to sitravatinib dose reduction and interruption), it is recommended to escalate sitravatinib dose to 100 mg once daily at the discretion of the investigators after discussion with patients.
Study: NCT06279494
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Orally (concentration 5-10ng/ml) from -1 to +100d post haplo-HSCT
Study: NCT06279494
Drug: Abatacept
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5mg/kg subcutaneous, -1/+5/+14/+28/+42/+56d post haplo-HSCT